Q4 2021
Released Feb 23, 2022, after the close
10-K filed Mar 3, 2022, 62 days after period end · 0001493152-22-005976
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.64M$2.64M derived+13.0% vs Q4 2020+2.3% vs Q3 2021
Net Income-$982.00K-$982.00K derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,411,000+8.4%
Operating Incomederived-$315,000N/M
Operating Cash Flowderived-$335,000N/M
Free Cash Flowderived-$335,000N/M
Margins · derived
Gross margin53.5%−2.3 pt vs Q4 2020
Operating margin-11.9%+18.9 pt vs Q4 2020
Net margin-37.2%−4.7 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.64M | $2.33M | $3.16M | $1.61M |
| Net Income | -$982.00K | -$759.00K | -$144.00K | -$725.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR